Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age45-90
SponsorUniversity of Colorado, Denver

About this trial

The overall goal of this study is to define the phenotype of Interstitial Lung Disease (ILD), and identify factors that predict radiologic progression in those with subclinical RA-ILD, in patients with rheumatoid arthritis (RA). The investigators hypothesize that there are common core elements (e.g. clinical features, genetic variants, and/or biologic markers) between other forms of ILD (e.g. idiopathic pulmonary fibrosis, IPF) and subclinical RA-ILD that places individuals at risk for the development of lung disease.

Eligibility criteria

Qualifiers

≥ 45years old

Diagnosis of RA using the 2010 American College of Rheumatology (ACR) criteria

Disqualifiers

Inability to give informed consent

Pregnant women

History of interstitial lung disease

Evidence of other causes of diffuse parenchymal lung disease such as infection, drug toxicity, other autoimmune processes, etc.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

750 Participants
are grouped into 2 trial groups

Sponsors and collaborators